Clinicians can use biomarkers to guide therapeutic decisions in estrogen receptor positive
(ER+) breast cancer. One such biomarker is cellular proliferation as evaluated by Ki-67. This …

Breast cancer is an intrinsically heterogeneous disease. In the world about 1 million cases of
breast cancer are diagnosed annually and more than 170000 are triple-negative …

Abstract Purpose: The value of Ki67 measured on residual disease after neoadjuvant
chemotherapy is not sufficiently described. Experimental Design: Participants of the …

Background The purpose of this study was (i) to test the hypothesis that combining Ki67 with
residual cancer burden (RCB) following neoadjuvant chemotherapy, as the residual …

Aim To investigate whether quantitative radiomics features extracted from dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) are associated with Ki67 expression of …

Objective The clinical feature of breast cancer is very heterogeneous because of the
variable prognostic factors impact its behaviour. The aim of study is to find the prognostic …

Background Salivary duct carcinoma (SDC) is a highly aggressive disease which often
metastasizes to distant sites, and there is no established standard therapy for this systemic …

Background In breast cancer, ER/PgR, HER2, and Ki-67 are important biological markers for
predicting prognosis and making effective treatment decisions. In addition, changes in …

Measurement of Ki-67, a marker of cell proliferation, has been associated with response to
therapy, but methods of measurement are controversial. Here we use a quantitative …

The neoadjuvant setting provides unquestionable clinical benefits for high-risk breast cancer
(BC) patients, mainly in terms of expansion of locoregional treatment options and prognostic …